Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Where Is Teva Pharmaceutical Finding Growth?

In today's world, most companies span several regions and sell across the world. As my Foolish colleague Morgan Housel notes, less than a third of S&P 500 revenue came from overseas 10 years ago. Today, more than half of the S&P 500's growth comes from overseas.

And that number is growing. The truth is that investors regularly underestimate how much demand comes from abroad. More importantly, for large, multinational corporations that have already established a presence in their home markets, much of their future growth comes from abroad.

With that in mind, today we're looking at Israel-based generic kingpin Teva Pharmaceutical (Nasdaq: TEVA  ) . We'll examine not only where its sales and earnings come from, but how its sales abroad have changed over time.

Where Teva Pharmaceutical’s sales were five years ago
Five years ago, Teva Pharmaceutical relied on North America for nearly 60% of its sales. Combined with European sales, the two markets contributed 89% of Teva’s total sales.

Source: Capital IQ, a division of Standard & Poor's.

Where Teva Pharmaceutical's sales are today
Today, Teva Pharmaceutical's sales haven’t changed as drastically as many of its peers in the pharmaceuticals business. While most large businesses continue to expand away from developed markets, Teva actually saw its percent of sales to North America increase to 62%.

Source: Capital IQ, a division of Standard & Poor's.

However, there’s also plenty of international opportunity ahead for the company. Teva’s international sales, as a proportion of its total sales, doubled from 5% in 2005 to 10% in 2010. While sales growth was fantastic across all segments of the company, its international segment saw the highest growth rates by far.


5-Year Total Sales Growth

North America 217%
Europe 158%
International 504%
Israel 84%

Source: Capital IQ, a division of Standard & Poor's.

Competitor checkup
One last point to check is how Teva Pharmaceutical's footprint compares to some of its peers across the broader pharmaceuticals and health care industry:


Geographic Area With Most Sales

Percent of Sales

Teva Pharmaceutical North America 62%
Novartis (NYSE: NVS  ) Other* 42%
Watson Pharmaceuticals (NYSE: WPI  ) United States 88%
Merck (NYSE: MRK  ) United States 44%

Source: Capital IQ, a division of Standard & Poor's. *In 2008, Novartis reclassified its sales. "Other" includes regions in Europe not including Switzerland, Germany, and France, in addition to Asia, Africa, and Australasia. In terms of a defined segment, the United States is Novartis’ largest segment.

Next to Watson, its closest generic medication peer in the group, Teva is truly a globe-trotter. Novartis has quite a large amount of international exposure, but its unit that offers generic medication -- Sandoz -- accounts for just 17% of the company’s sales. Finally, Merck -- a company that fears the dreaded “patent cliff” --  is the most geographically diversified of the bunch.

The important point to remember with Teva is that there are a large amount of pharmaceutical patents going offline between now and 2013. As these patents expire, Teva should see its sales continue to climb, especially in already booming international markets.

Keep searching
If you're looking to stay updated on Teva Pharmaceuticals, or any other companies listed above, make sure to add them to our watchlist service, My Watchlist. It's free, and it helps you constantly stay updated on news and analysis on your favorite companies.

Eric Bleeker owns no shares of any companies listed above. The Motley Fool owns shares of Teva Pharmaceutical Industries. Motley Fool newsletter services have recommended buying shares of Novartis and Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy

Read/Post Comments (0) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1512988, ~/Articles/ArticleHandler.aspx, 10/25/2016 4:57:14 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 7 hours ago Sponsored by:
DOW 18,223.03 77.32 0.43%
S&P 500 2,151.33 10.17 0.47%
NASD 5,309.83 52.43 1.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/24/2016 4:00 PM
TEVA $43.50 Down -0.50 -1.14%
Teva Pharmaceutica… CAPS Rating: ****
AGN $225.93 Down -4.54 -1.97%
Allergan CAPS Rating: ****
MRK $60.75 Down -0.45 -0.74%
Merck and Co. CAPS Rating: ****
NVS $75.45 Down -0.09 -0.12%
Novartis CAPS Rating: ****